Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 14
HOS-086223 · Präparat HOS-083284
Fostamatinib Co-administration of fostamatinib with ritonavir may increase fostamatinib
metabolite R406 exposure resulting in dose-related adverse events such as
hepatotoxicity, neutropenia, hypertension, or diarrhoea. Refer to the fostamatinib
SmPC for dose reduction recommendations if such events occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage b45c2bea8b8de4f2edce7c92a4eb7ddf682ac35f27d445f0b8195555eb763c89 · Zeichen 18975–19416 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46
HOS-086424 · Präparat HOS-083284
Fostamatinib Co-administration of fostamatinib with ritonavir may increase fostamatinib metabolite
R406 exposure resulting in dose-related adverse events such as hepatotoxicity,
neutropenia, hypertension, or diarrhoea. Refer to the fostamatinib SmPC for dose
reduction recommendations if such events occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 5aa5f0d7033075dd18357ba4c3347f6a1e84b4c4bf6a12df09ec20499e2fd040 · Zeichen 19786–20231 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 14
HOS-108873 · Präparat HOS-093083
Due to BCRP (breast cancer
resistance protein/ABCG2) and
acute P-gp inhibition by
lopinavir/ritonavir.
Ceritinib Serum concentrations may be Caution should be exercised in
increased due to CYP3A and administering ceritinib with
P-gp inhibition by Kaletra. Refer to the ceritinib
lopinavir/ritonavir. SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to ceritinib.
Most tyrosine kinase Most tyrosine kinase inhibitors Careful monitoring of the tolerance
inhibitors such as dasatinib such as dasatinib and nilotinib, of these anticancer agents.
and nilotinib, vincristine, also vincristine and vinblastine:
vinblastine Risk of increased adverse events
due to higher serum
concentrations because of
CYP3A4 inhibition by
lopinavir/ritonavir.
Encorafenib Serum concentrations may be Co-administration of encorafenib
increased due to CYP3A with Kaletra may increase
inhibition by lopinavir/ritonavir. encorafenib exposure which may
increase the risk of toxicity,
including the risk of serious
adverse events such as QT interval
prolongation. Co-administration of
encorafenib and Kaletra should be
avoided. If the benefit is
considered to outweigh the risk and
Kaletra must be used, patients
should be carefully monitored for
safety.
Fostamatinib Increase in fostamatinib Co-administration of fostamatinib
metabolite R406 exposure. with Kaletra may increase
fostamatinib metabolite R406
exposure resulting in dose-related
adverse events such as
hepatotoxicity, neutropenia,
hypertension, or diarrhoea. Refer
to the fostamatinib SmPC for dose
reduction recommendations if such
events occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ceritinib (HOS-086215) dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) encorafenib (HOS-086222) tyrosine (HOS-108875) nilotinib (HOS-086218) fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f5ee8e193a63fbfc6f13a97d10087b8507fd2ece74570ff6426e080b1664ce91 · Zeichen 15461–19027 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-109008 · Präparat HOS-093083
Due to BCRP (breast cancer
resistance protein/ABCG2) and
acute P-gp inhibition by
lopinavir/ritonavir.
Ceritinib Serum concentrations may be Caution should be exercised in
increased due to CYP3A and P-gp administering ceritinib with Kaletra.
inhibition by lopinavir/ritonavir. Refer to the ceritinib SmPC for
dosage adjustment recommendations.
Monitor for ADRs related to
ceritinib.
Most tyrosine kinase Most tyrosine kinase inhibitors Careful monitoring of the tolerance
inhibitors such as such as dasatinib and nilotinib, of these anticancer agents.
dasatinib and nilotinib, also vincristine and vinblastine:
vincristine, vinblastine Risk of increased adverse events
due to higher serum
concentrations because of
CYP3A4 inhibition by
lopinavir/ritonavir.
Encorafenib Serum concentrations may be Co-administration of encorafenib
increased due to CYP3A with Kaletra may increase
inhibition by lopinavir/ritonavir. encorafenib exposure which may
increase the risk of toxicity,
including the risk of serious adverse
events such as QT interval
prolongation. Co-administration of
encorafenib and Kaletra should be
avoided. If the benefit is considered
to outweigh the risk and Kaletra must
be used, patients should be carefully
monitored for safety.
Fostamatinib Increase in fostamatinib Co-administration of fostamatinib
metabolite R406 exposure. with Kaletra may increase
fostamatinib metabolite R406
exposure resulting in dose-related
adverse events such as
hepatotoxicity, neutropenia,
hypertension, or diarrhoea. Refer to
the fostamatinib SmPC for dose
reduction recommendations if such
events occur.
Ibrutinib Serum concentrations may be Co-administration of ibrutinib and
increased due to CYP3A Kaletra may increase ibrutinib
inhibition by lopinavir/ritonavir. exposure which may increase the risk
of toxicity including risk of tumor
lysis syndrome. Co-administration of
ibrutinib and Kaletra should be
avoided. If the benefit is considered
to outweigh the risk and Kaletra must
be used, reduce the ibrutinib dose to
140 mg and monitor patient closely
for toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ceritinib (HOS-086215) dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) encorafenib (HOS-086222) tyrosine (HOS-108875) nilotinib (HOS-086218) fostamatinib (HOS-086224) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage fdf43c7972e8bad9c23624bb28b17126727cc97af42d31ac6b82ada1aa394853 · Zeichen 15203–19620 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 86–87
HOS-109083 · Präparat HOS-093083
86
Fostamatinib Increase in fostamatinib Co-administration of fostamatinib
metabolite R406 exposure. with Kaletra may increase
fostamatinib metabolite R406
exposure resulting in dose-related
adverse events such as
hepatotoxicity, neutropenia,
hypertension, or diarrhoea. Refer to
the fostamatinib SmPC for dose
reduction recommendations if such
events occur.
Ibrutinib Serum concentrations may be Co-administration of ibrutinib and
increased due to CYP3A Kaletra may increase ibrutinib
inhibition by lopinavir/ritonavir. exposure which may increase the
risk of toxicity including risk of
tumor lysis syndrome.
Co-administration of ibrutinib and
Kaletra should be avoided. If the
benefit is considered to outweigh
the risk and Kaletra must be used,
reduce the ibrutinib dose to 140 mg
and monitor patient closely for
toxicity.
Neratinib Serum concentrations may be Concomitant use of neratinib with
increased due to CYP3A Kaletra is contraindicated due to
inhibition by ritonavir. serious and/or life-threatening
potential reactions including
hepatotoxicity (see section 4.3).
Venetoclax Due to CYP3A inhibition by Serum concentrations may be
lopinavir/ritonavir. increased due to CYP3A inhibition
by lopinavir/ritonavir, resulting in
increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see
section 4.3 and refer to the
venetoclax SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): neratinib (HOS-086142) venetoclax (HOS-086143) fostamatinib (HOS-086224) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c9bb2caafb1e7537cc621ca3de26840b2503f0c9b5c58c2565a4a56335290183 · Zeichen 17969–20931 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 21–22
HOS-112110 · Präparat HOS-093615
21
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
KINASE INHIBITORS
Fostamatinib The mechanism of interaction is CYP3A4 Concomitant use of fostamatinib
inhibition by atazanavir and/or ritonavir. with REYATAZ (with or without
ritonavir) may increase the plasma
concentration of R406, the active
metabolite of fostamatinib. Monitor
for toxicities of R406 exposure
resulting in dose-related adverse
events such as hepatotoxicity and
neutropenia. Fostamatinib dose
reduction may be required.
HERBAL PRODUCTS
St. John’s wort (Hypericum Concomitant use of St. John's wort with Co-administration of REYATAZ
perforatum) REYATAZ may be expected to result in with products containing St. John's
significant reduction in plasma levels of wort is contraindicated.
atazanavir. This effect may be due to an
induction of CYP3A4. There is a risk of
loss of therapeutic effect and development
of resistance (see section 4.3).
HORMONAL CONTRACEPTIVES
Ethinyloestradiol 25 μg + Ethinyloestradiol AUC: ↓19% (↓25% If an oral contraceptive is
norgestimate ↓13%) administered with
(atazanavir 300 mg once daily Ethinyloestradiol Cmax: ↓16% (↓26% ↓5%) REYATAZ/ritonavir, it is
with ritonavir 100 mg once daily) Ethinyloestradiol Cmin: ↓37% (↓45% recommended that the oral
↓29%) contraceptive contain at least 30 μg
of ethinyloestradiol and that the
Norgestimate AUC: ↑85% (↑67% ↑105%) patient be reminded of strict
Norgestimate Cmax: ↑68% (↑51% ↑88%) compliance with this contraceptive
Norgestimate Cmin: ↑102% (↑77% ↑131%) dosing regimen. Co-administration
of REYATAZ/ritonavir with other
While the concentration of hormonal contraceptives or oral
ethinyloestradiol was increased with contraceptives containing
atazanavir given alone, due to both UGT progestogens other than
and CYP3A4 inhibition by atazanavir, the norgestimate has not been studied,
net effect of atazanavir/ritonavir is a and therefore should be avoided.
decrease in ethinyloestradiol levels An alternate reliable method of
because of the inducing effect of ritonavir. contraception is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) ritonavir (HOS-084521) fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 88d66ceb04488e865827a92aeb749971b0146f4e3c2b6030736f981f76f4f80b · Zeichen 61675–65625 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 57–58
HOS-112198 · Präparat HOS-093615
57
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
KINASE INHIBITORS
Fostamatinib The mechanism of interaction is CYP3A4 Concomitant use of
inhibition by atazanavir and/or ritonavir. fostamatinib with REYATAZ
(with or without ritonavir) may
increase the plasma
concentration of R406, the
active metabolite of
fostamatinib. Monitor for
toxicities of R406 exposure
resulting in dose-related
adverse events such as
hepatotoxicity and neutropenia.
Fostamatinib dose reduction
may be required.
HERBAL PRODUCTS
St. John’s wort (Hypericum Concomitant use of St. John's wort with Co-administration of
perforatum) REYATAZ may be expected to result in REYATAZ with products
significant reduction in plasma levels of containing St. John's wort is
atazanavir. This effect may be due to an contraindicated.
induction of CYP3A4. There is a risk of
loss of therapeutic effect and development
of resistance (see section 4.3).
HORMONAL CONTRACEPTIVES
Ethinyloestradiol 25 μg + Ethinyloestradiol AUC: ↓19% (↓25% If an oral contraceptive is
norgestimate ↓13%) administered with
(atazanavir 300 mg once daily Ethinyloestradiol Cmax: ↓16% (↓26% ↓5%) REYATAZ/ritonavir, it is
with ritonavir 100 mg once Ethinyloestradiol Cmin: ↓37% (↓45% ↓29%) recommended that the oral
daily) contraceptive contain at least
Norgestimate AUC: ↑85% (↑67% ↑105%) 30 μg of ethinyloestradiol and
Norgestimate Cmax: ↑68% (↑51% ↑88%) that the patient be reminded of
Norgestimate Cmin: ↑102% (↑77% ↑131%) strict compliance with this
contraceptive dosing regimen.
While the concentration of Co-administration of
ethinyloestradiol was increased with REYATAZ/ritonavir with
atazanavir given alone, due to both UGT other hormonal contraceptives
and CYP3A4 inhibition by atazanavir, the or oral contraceptives
net effect of atazanavir/ritonavir is a containing progestogens other
decrease in ethinyloestradiol levels because than norgestimate has not been
of the inducing effect of ritonavir. studied, and therefore should
be avoided. An alternate
The increase in progestin exposure may reliable method of
lead to related side effects (e.g., insulin contraception is recommended.
resistance, dyslipidemia, acne and
spotting), thus possibly affecting the
compliance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): norgestimate (HOS-110544) lead (HOS-085592) ritonavir (HOS-084521) fostamatinib (HOS-086224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage b9defd86fb4b9ba4d41aa8bd1a8e8d62460525287329f28f7b9f1aafde957e42 · Zeichen 64152–68533 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.